May 2025 – MiP Pharma, a portfolio company of capiton, announces the successful sale of its production site in Homburg/Saar to the Famar Group, a globally operating pharmaceutical CDMO. The Famar Group will integrate the facility into its global production network and further develop it. For MiP Pharma, this step is a key part of its growth strategy, which will focus on the distribution of its own pharmaceutical products in the future.
Over the past two years, MiP Pharma, supported by capiton, has made significant investments in the expansion, consolidation, and modernization of the site. These measures included the installation of new packaging lines, the expansion of laboratory capacities, and extensive technical upgrades. These improvements have transformed the facility into a highly attractive site for international partners.
Alexander Zamora, Partner at capiton, commented: “We are proud to have actively supported the expansion of the Homburg site. The sale not only ensures the sustainable development of the site but also lays the foundation for MiP Pharma’s future growth. This is a pivotal step in the company’s strategic direction.”
Dr. Friedrich Sernetz, CEO of MiP Pharma, added: “Thanks to the investments, the Homburg facility has become an attractive site for global pharmaceutical specialists. The sale enables us to focus on our core competency – the distribution of our pharmaceutical products – and to accelerate our growth.”
With this transaction, capiton AG continues its successful strategy of actively supporting companies in their transformation and growth while creating sustainable value.
About MiP Pharma
The MiP Pharma Group markets prescription generics, primarily antibiotics, as well as over-the-counter medicines and medical devices. The main markets are Germany, Poland, and other Eastern European countries. The sales focus is on the hospital business and addressing specialized medical groups. With over 200 employees and around 400 marketing authorizations, MiP Pharma generated sales of approximately €50 million in the last financial year. Since November 2020, MiP Pharma has been part of the portfolio of the Berlin-based private equity firm capiton AG.
About capiton
capiton is an independent, owner-managed private equity firm with a total fund volume of €1.6 billion. The current investment portfolio of capiton AG includes 18 medium-sized companies. As an equity partner, capiton supports management buy-outs and growth financing for established medium-sized businesses.
About JR Pet Products
JR Pet Products is a UK-based company offering natural chews and high-quality treats for dogs. Founded in 2012 by Jonathan and Rebecca Davies and Stephen Tandy, JR Pet Products has become a leader in the premium dog market.
The company has a strong focus on quality and innovation and built a successful multi-channel distribution with a strong network of B2B partners and direct consumer access (D2C).
About capiton
capiton is an independent, owner-managed private equity firm with over €1.6 billion in managed funds. Its current portfolio includes 18 mid-sized companies, supporting management buyouts and growth financing for established businesses.
About Patria Investments
Patria is a leading alternative investment firm with over 35 years of history specialized in key resilient sectors. With over US $44 billion in assets under management and a global presence, it aims to provide consistent returns in attractive long term investment opportunities while creating sustainable value for society.
About Reimann Investors
Reimann Investors is a family office and corporate group representing members of the Reimann entrepreneurial family. The firm focuses on highly liquid capital market investments and direct investments in high-growth digital businesses in areas like digital commerce, FinTech, and SaaS.
About Venture Stars
Venture Stars is a Munich-based venture capital fund specializing in early-stage investments in innovative B2C and B2B digital business models. Founded by Martin Junker, Florian Calmbach, and Stefan Pfannmöller, the firm manages three funds, with investments typically ranging between €0.5 million and €5 million per portfolio company. As a former company builder, Venture Stars offers support beyond capital, including strategic know-how, networking, and operational advice in areas such as organizational development and financing.
